{
    "id": 6188,
    "fullName": "ERBB3 T355I",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ERBB3 (HER3) T355I lies within the extracellular domain of the Erbb3 (Her3) protein (UniProt.org). T355I confers a gain of function to the Erbb3 (Her3) protein as demonstrated by increased proliferation of ER-positive cells as compared to wild-type ERBB3 (HER3), increased phosphorylation of downstream signaling molecules, and activation of the MAPK pathway in culture (PMID: 29963236).",
            "references": [
                {
                    "id": 11673,
                    "pubMedId": 29963236,
                    "title": "Activating HER3 mutations in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29963236"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2065,
        "geneSymbol": "ERBB3",
        "terms": [
            "ERBB3",
            "c-erbB-3",
            "c-erbB3",
            "ErbB-3",
            "erbB3-S",
            "FERLK",
            "HER3",
            "LCCS2",
            "MDA-BF-1",
            "p180-ErbB3",
            "p45-sErbB3",
            "p85-sErbB3"
        ]
    },
    "variant": "T355I",
    "createDate": "05/16/2015",
    "updateDate": "01/11/2019",
    "referenceTranscriptCoordinates": {
        "id": 123515,
        "transcript": "NM_001982",
        "gDna": "chr12:g.56088823C>T",
        "cDna": "c.1064C>T",
        "protein": "p.T355I",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15636,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Faslodex (fulvestrant) did not significantly reduce cell proliferation of estrogen-receptor positive breast cancer cells expressing ERBB3 (HER3) T355I in culture relative to control and combination treatments (PMID: 29963236).",
            "molecularProfile": {
                "id": 6039,
                "profileName": "ERBB3 T355I"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11673,
                    "pubMedId": 29963236,
                    "title": "Activating HER3 mutations in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29963236"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15635,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tykerb (lapatinib) and SCH772984 resulted in a synergistic effect, demonstrating decreased colony formation and reduced cell proliferation, but to a lesser degree than Tykerb (lapatinib) combined with Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB3 (HER3) T355I in culture (PMID: 29963236).",
            "molecularProfile": {
                "id": 6039,
                "profileName": "ERBB3 T355I"
            },
            "therapy": {
                "id": 7682,
                "therapyName": "Lapatinib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11673,
                    "pubMedId": 29963236,
                    "title": "Activating HER3 mutations in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29963236"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15632,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Faslodex (fulvestrant) and Tykerb (lapatinib) resulted in a synergistic effect, demonstrating decreased cell proliferation and reduced colony formation of estrogen-receptor positive breast cancer cells expressing ERBB3 (HER3) T355I in culture (PMID: 29963236).",
            "molecularProfile": {
                "id": 6039,
                "profileName": "ERBB3 T355I"
            },
            "therapy": {
                "id": 7681,
                "therapyName": "Fulvestrant + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11673,
                    "pubMedId": 29963236,
                    "title": "Activating HER3 mutations in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29963236"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15633,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Tykerb (lapatinib) did not significantly reduce the proliferation of estrogen-receptor positive breast cancer cells expressing ERBB3 (HER3) T355I in culture relative to control and combination treatments (PMID: 29963236).",
            "molecularProfile": {
                "id": 6039,
                "profileName": "ERBB3 T355I"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11673,
                    "pubMedId": 29963236,
                    "title": "Activating HER3 mutations in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29963236"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15634,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with SCH772984 did not significantly reduce the proliferation of estrogen-receptor positive breast cancer cells expressing ERBB3 (HER3) T355I in culture relative to control and combination treatments (PMID: 29963236).",
            "molecularProfile": {
                "id": 6039,
                "profileName": "ERBB3 T355I"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11673,
                    "pubMedId": 29963236,
                    "title": "Activating HER3 mutations in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29963236"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15659,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Nerlynx (neratinib) resulted in reduced colony formation of ERBB2 (HER2)-overexpressing breast cancer cells expressing ERBB3 (HER3) T355I in culture relative to control treatment, however, at a much greater concentration than the minimal concentration required for ERBB2 (HER2) activating mutations (PMID: 29963236).",
            "molecularProfile": {
                "id": 31130,
                "profileName": "ERBB2 over exp ERBB3 T355I"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11673,
                    "pubMedId": 29963236,
                    "title": "Activating HER3 mutations in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29963236"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15646,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Perjeta (pertuzumab) did not result in significantly decreased colony formation of ERBB2 (HER2)-overexpressing breast cancer cells expressing ERBB3 (HER3) T355I in culture relative to control treatment (PMID: 29963236).",
            "molecularProfile": {
                "id": 31130,
                "profileName": "ERBB2 over exp ERBB3 T355I"
            },
            "therapy": {
                "id": 856,
                "therapyName": "Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11673,
                    "pubMedId": 29963236,
                    "title": "Activating HER3 mutations in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29963236"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15647,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Herceptin (trastuzumab) did not result in significantly decreased colony formation of ERBB2 (HER2)-overexpressing breast cancer cells expressing ERBB3 (HER3) T355I in culture relative to control treatment (PMID: 29963236).",
            "molecularProfile": {
                "id": 31130,
                "profileName": "ERBB2 over exp ERBB3 T355I"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11673,
                    "pubMedId": 29963236,
                    "title": "Activating HER3 mutations in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29963236"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15654,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Tykerb (lapatinib) did not lead to reduced proliferation of ERBB2 (HER2)-overexpressing breast cancer cells expressing ERBB3 (HER3) T355I in culture relative to control treatment (PMID: 29963236).",
            "molecularProfile": {
                "id": 31130,
                "profileName": "ERBB2 over exp ERBB3 T355I"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11673,
                    "pubMedId": 29963236,
                    "title": "Activating HER3 mutations in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29963236"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15645,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment with Herceptin (trastuzumab) and Perjeta (pertuzumab) did not result in significantly decreased colony formation of ERBB2 (HER2)-overexpressing breast cancer cells expressing ERBB3 (HER3) T355I in culture relative to control treatment (PMID: 29963236).",
            "molecularProfile": {
                "id": 31130,
                "profileName": "ERBB2 over exp ERBB3 T355I"
            },
            "therapy": {
                "id": 1389,
                "therapyName": "Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11673,
                    "pubMedId": 29963236,
                    "title": "Activating HER3 mutations in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29963236"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 6039,
            "profileName": "ERBB3 T355I",
            "profileTreatmentApproaches": [
                {
                    "id": 18607,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "ERBB3 T355I"
                },
                {
                    "id": 18609,
                    "name": "HER3 Inhibitor",
                    "profileName": "ERBB3 T355I"
                },
                {
                    "id": 18608,
                    "name": "HER2 Inhibitor",
                    "profileName": "ERBB3 T355I"
                }
            ]
        },
        {
            "id": 31130,
            "profileName": "ERBB2 over exp ERBB3 T355I",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 123515,
            "transcript": "NM_001982",
            "gDna": "chr12:g.56088823C>T",
            "cDna": "c.1064C>T",
            "protein": "p.T355I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}